JAZZ

Jazz Pharmaceuticals plc Press Releases

$162.18
*  
2.07
1.26%
Get JAZZ Alerts
*Delayed - data as of Sep. 4, 2015  -  Find a broker to begin trading JAZZ now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By

Jazz Pharmaceuticals Announces Second Quarter 2015 Financial Results
8/5/2015 4:05:00 PM - PR Newswire
▼-15.49 % Price Change since this news event. The Volume Ratio is 1.65.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Jazz Pharmaceuticals to Report 2015 Second Quarter Financial Results on August 5, 2015
7/22/2015 4:05:00 PM - PR Newswire
▼-12.04 % Price Change since this news event. The Volume Ratio is 1.27.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8
7/1/2015 4:05:00 PM - PR Newswire
▼-8.44 % Price Change since this news event. The Volume Ratio is 0.46.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Aytu BioScience Acquires Commercial-Stage Prostate Cancer Biologic
6/9/2015 8:00:00 AM - PR Newswire
▼-6.91 % Price Change since this news event. The Volume Ratio is 1.32.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of Excessive Daytime Sleepiness (EDS) Associated with Narcolepsy or with Obstructive Sleep Apnea (OSA)
6/8/2015 9:05:00 AM - PR Newswire
▼-10.15 % Price Change since this news event. The Volume Ratio is 2.43.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day